SEOUL, South Korea, Nov. 3, 2022 /PRNewswire/ — Robert Yu, CEO of Yuyu Pharma, has attended biopharmaceutical conferences in Germany, BIO-Europe and CPHI. The objective is to explore expansion opportunities in international markets, such as Europe.
During his attendance at BIO-Europe (Leipzig) and CPHI (Frankfurt), Robert Yu has focused on meeting with contract research organizations, key opinion leaders and potential clinical centers to prepare for the drug’s US and European clinical trials. for Yuyu’s dry eye, YP-P10, and for androgenetic alopecia drug, DUT. Yuyu Pharma is currently conducting phase 2 clinical trials for YP-P10 in the United States at 7 centers with 240 patients.
In addition, Robert Yu is scheduled to meet with pharmaceutical companies from around the world to discuss potential opportunities for collaboration, as well as meeting with European officials regarding regulatory issues and drug registration. Robert Yu explained, “Attending such a conference provides an opportunity to showcase the company and the portfolio of drug discovery programs under development. We have received positive feedback on Yuyu’s new drug portfolio and hope that this will become commercial success in the future.
About Yuyu Pharma
Yuyu Pharma (KRX: 000220) is a Korean pharmaceutical company founded in 1941 that manufactures and distributes pharmaceuticals, medical devices, and food supplements. The company is also committed to developing innovative therapies in the areas of neurology, urology and ophthalmology. Yuyu’s mission is to improve the quality of life and increase the well-being of all people through the development of innovative health products and services.
Media ContactSean Yoonhjyoon@yuyu.co.kr
Photo – link
View original content: enlace
